There was also a trend towards an increased proportion of Tbet+/CD21low cells within the IgM+ MBC subset in CIS/MS patients compared to controls (Figures 2E, F), no difference between CIS and MS patients was observed for any of these subsets (Supplementary Figure 4). The gene discussed is CD40LG; the disease is in situ carcinoma.